<DOC>
	<DOC>NCT02817906</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.</brief_summary>
	<brief_title>ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<criteria>Clinical diagnosis of probable Alzheimer's disease Clinically significant symptoms of agitation secondary to probable Alzheimer's disease Able to attend outpatient clinic visits with primary caregiver Unable to comply with study procedures Considered medically inappropriate for study participation</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>